Iwata Hiroji
Department of Breast Oncology, Aichi Cancer Center Hospital, Japan.
Breast Cancer. 2007;14(2):150-5. doi: 10.2325/jbcs.955.
Trastuzumab (Herceptin) has many benefits for metastatic breast cancer patients with HER2 overexpression/amplification. Trastuzumab alone or trastuzumab in combination with chemotherapy regimens are standard treatment worldwide as first line therapy for metastatic breast cancer patients with HER2 overexpression/amplification. Furthermore, an international collaboration for adjuvant trastuzumab trials showed last year that trastuzumab treatment improves disease-free and overall survival after or in combination with adjuvant chemotherapy. However, there are many uncertain issues concerning trastuzumab adjuvant and metastatic treatment, such as treatment beyond disease progression (PD), combination with hormone therapy, duration of adjuvant treatment, and cardiac safety of long term treatment.
曲妥珠单抗（赫赛汀）对HER2过表达/扩增的转移性乳腺癌患者有诸多益处。单独使用曲妥珠单抗或曲妥珠单抗联合化疗方案是全球范围内HER2过表达/扩增的转移性乳腺癌患者一线治疗的标准疗法。此外，一项关于辅助性曲妥珠单抗试验的国际合作去年表明，曲妥珠单抗治疗在辅助化疗后或与之联合使用时可改善无病生存期和总生存期。然而，关于曲妥珠单抗辅助治疗和转移性治疗存在许多不确定问题，如疾病进展（PD）后的治疗、与激素治疗的联合使用、辅助治疗的持续时间以及长期治疗的心脏安全性。
